[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]

N I Kurysheva; A A Shpak; E E Ioĭleva; L I Galanter; N D Nagornova; N Iu Shubina; N N Shlyshalova

[Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone]

Vestn Oftalmol. 2001 Jul-Aug;117(4):5-8.

[Article in Russian]

Authors

N I Kurysheva, A A Shpak, E E Ioĭleva, L I Galanter, N D Nagornova, N Iu Shubina, N N Shlyshalova

PMID: 11569188

Abstract

A complex of neuroprotective therapy, including a new Russian neuropeptide semax, was used in the treatment of glaucoma patients with normalized ophthalmic tone. Electrophysiological and computer methods of examination demonstrated the advantages of new therapy over traditional neuroprotective treatment for glaucoma. The efficiency is due to pathogenetic activity of semax possessing both neuroprotective and neurotrophic effects.

Publication types

Comparative Study
English Abstract

MeSH terms

Adrenocorticotropic Hormone / administration & dosage
Adrenocorticotropic Hormone / analogs & derivatives
Adrenocorticotropic Hormone / therapeutic use*
Aged
Female
Glaucoma / complications*
Humans
Intraocular Pressure
Male
Middle Aged
Neuroprotective Agents / administration & dosage
Neuroprotective Agents / therapeutic use*
Optic Nerve Diseases / drug therapy*
Peptide Fragments / administration & dosage
Peptide Fragments / therapeutic use*
Time Factors
Visual Field Tests

Substances

Neuroprotective Agents
Peptide Fragments
ACTH (4-7), Pro-Gly-Pro-
Adrenocorticotropic Hormone